COVID-19 Pill Research at UNC Helps Produce Effective Oral Antiviral Treatment

Merck announced strong clinical trial results for molnupiravir, the first oral antiviral drug to treat COVID-19, and will now seek FDA authorization. Clinical trials led by researchers at the University of North Carolina at Chapel Hill showed that the pill treatment eliminates the virus in patients. Drs. William Fischer and Tim Sheahan talk about the findings of the clinical trial.